KOD · XBRL financial data

Kodiak Sciences financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (KOD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	107	217	268	206	126	182
General and administrative	29	50	74	71	61	52
Total operating expenses	136	267	341	277	187	234
Operating income (loss)	(136)	(267)	(341)	(277)	(187)	(234)
Interest income	3	0	7	17	11	5
Interest expense	0	0	0	0	0	0
Other income (expense)	0	(0)	1	0	(1)	(0)
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(133)	(267)	(334)	(260)	(176)	(230)
Earnings per share, basic USD per share	(2.91)	(5.16)	(6.39)	(4.97)	(3.35)	(4.32)
Earnings per share, diluted USD per share	(2.91)	(5.16)	(6.39)	(4.97)	(3.35)	(4.32)
Weighted average shares, basic millions of shares	46	52	52	52	53	53
Weighted average shares, diluted millions of shares	46	52	52	52	53	53

Fiscal years (KOD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	944	732	190	286	168	210
Marketable securities	25	0	289	0	—	—
Prepaid and other current assets	3	3	7	4	4	5
Total current assets	972	735	486	289	172	215
Property and equipment, net	5	41	56	120	102	85
Right-of-use asset	74	67	59	55	47	37
Total assets	1,067	904	667	479	336	352
Accounts payable	9	12	9	14	4	13
Accrued liabilities	20	48	33	18	11	21
Total current liabilities	31	65	52	42	26	46
Lease liability, non-current	75	76	78	72	60	47
Total liabilities	207	241	230	214	185	194
Accumulated deficit	(291)	(558)	(892)	(1,153)	(1,329)	(1,559)
Total stockholders' equity	861	663	436	266	150	157
Total liabilities and equity	1,067	904	667	479	336	352
Common shares outstanding (cover page) millions of shares	51	52	52	53	53	62

Fiscal years (KOD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(133)	(267)	(334)	(260)	(176)	(230)
Stock-based compensation	31	6	106	89	60	59
Net cash from operating activities	(83)	(182)	(206)	(154)	(117)	(136)
Purchases of property and equipment	4	17	37	41	0	1
Net cash from investing activities	105	(39)	(337)	249	(1)	(1)
Proceeds from issuing common stock	612	0	0	—	—	—
Net cash from financing activities	717	8	2	0	1	178

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Kodiak Sciences	126	not reported	(46)*	62.8M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Alector	60	3.3	(34)*	111.7M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Skye Bioscience	8.1	not reported	(7.1)*	35.4M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Protalix BioTherapeutics	27	20	(10)*	80.6M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Fate Therapeutics	32	2.1	(23)	119.8M	6.6 quarters	Q2 FY26 10-QJun 30, 2026
Caribou Biosciences	26	1.5	(23)*	107.2M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Protara Therapeutics	17	not reported	(15)*	59.1M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
TuHURA Biosciences	1	not reported	(8.6)*	63.7M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Enanta Pharmaceuticals	33	14	(10)*	29.1M	19.0 quarters	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.